| # | Title | Journal | Year | Citations |
|---|
| 1 | Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study | European Journal of Cancer, Supplement | 2006 | 713 |
| 2 | Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes | European Journal of Cancer, Supplement | 2006 | 474 |
| 3 | Melanoma epidemiology, biology and prognosis | European Journal of Cancer, Supplement | 2013 | 178 |
| 4 | Beyond treatment – Psychosocial and behavioural issues in cancer survivorship research and practice | European Journal of Cancer, Supplement | 2014 | 177 |
| 5 | Sexual dysfunction and infertility as late effects of cancer treatment | European Journal of Cancer, Supplement | 2014 | 161 |
| 6 | Bases and rationale of the electrochemotherapy | European Journal of Cancer, Supplement | 2006 | 147 |
| 7 | Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy | European Journal of Cancer, Supplement | 2006 | 126 |
| 8 | Cardiovascular disease after cancer therapy | European Journal of Cancer, Supplement | 2014 | 110 |
| 9 | Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer | European Journal of Cancer, Supplement | 2010 | 107 |
| 10 | The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses | European Journal of Cancer, Supplement | 2006 | 101 |
| 11 | Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors | European Journal of Cancer, Supplement | 2013 | 100 |
| 12 | Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions | European Journal of Cancer, Supplement | 2014 | 82 |
| 13 | Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice | European Journal of Cancer, Supplement | 2012 | 73 |
| 14 | Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients | European Journal of Cancer, Supplement | 2007 | 60 |
| 15 | Current knowledge and future research directions in treatment-related second primary malignancies | European Journal of Cancer, Supplement | 2014 | 59 |
| 16 | Primary antifungal prophylaxis in leukaemia patients | European Journal of Cancer, Supplement | 2007 | 57 |
| 17 | Immunotherapy of melanoma | European Journal of Cancer, Supplement | 2013 | 53 |
| 18 | Depression in cancer patients | European Journal of Cancer, Supplement | 2013 | 53 |
| 19 | Empirical antifungal therapy in neutropaenic cancer patients with persistent fever | European Journal of Cancer, Supplement | 2007 | 51 |
| 20 | Anxiety and sleep disorders in cancer patients | European Journal of Cancer, Supplement | 2013 | 48 |
| 21 | Cancer survivorship: A positive side-effect of more successful cancer treatment | European Journal of Cancer, Supplement | 2014 | 47 |
| 22 | Urothelial carcinoma management in elderly or unfit patients | European Journal of Cancer, Supplement | 2016 | 45 |
| 23 | Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients | European Journal of Cancer, Supplement | 2007 | 43 |
| 24 | Role of contrast-enhanced ultrasound in the blinded assessment of focal liver lesions in comparison with MDCT and CEMRI: Results from a multicentre clinical trial | European Journal of Cancer, Supplement | 2008 | 43 |
| 25 | Clinical considerations for biosimilar antibodies | European Journal of Cancer, Supplement | 2013 | 42 |
| 26 | Chemotherapy-related changes in cognitive functioning | European Journal of Cancer, Supplement | 2013 | 41 |
| 27 | Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations | European Journal of Cancer, Supplement | 2013 | 41 |
| 28 | 3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) | European Journal of Cancer, Supplement | 2007 | 38 |
| 29 | 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) | European Journal of Cancer, Supplement | 2009 | 36 |
| 30 | Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy | European Journal of Cancer, Supplement | 2006 | 34 |
| 31 | Limitations to the use of carboplatin-based therapy in advanced ovarian cancer | European Journal of Cancer, Supplement | 2014 | 32 |
| 32 | 56 POSTER Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intrvenous administration in rodents and monkeys | European Journal of Cancer, Supplement | 2006 | 31 |
| 33 | Use of contrast-enhanced intraoperative ultrasonography during liver surgery for colorectal cancer liver metastases – Its impact on operative outcome. Analysis of a prospective cohort study | European Journal of Cancer, Supplement | 2008 | 30 |
| 34 | Molecular profile of lung cancer in never smokers | European Journal of Cancer, Supplement | 2013 | 30 |
| 35 | PS10 Late breaking Prophylactic use of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine reduces cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS) risk | European Journal of Cancer, Supplement | 2005 | 29 |
| 36 | 2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let) | European Journal of Cancer, Supplement | 2007 | 29 |
| 37 | Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of electrochemotherapy | European Journal of Cancer, Supplement | 2006 | 27 |
| 38 | Surgical treatment of early-stage non-small-cell lung cancer | European Journal of Cancer, Supplement | 2013 | 27 |
| 39 | Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management | European Journal of Cancer, Supplement | 2007 | 26 |
| 40 | 6521 POSTER Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) | European Journal of Cancer, Supplement | 2007 | 26 |
| 41 | 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) | European Journal of Cancer, Supplement | 2009 | 26 |
| 42 | 23LBA BEAM: A randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma | European Journal of Cancer, Supplement | 2009 | 25 |
| 43 | 6503 Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) | European Journal of Cancer, Supplement | 2009 | 23 |
| 44 | Angiogenesis as a new target for cancer control | European Journal of Cancer, Supplement | 2003 | 22 |
| 45 | Anastrozole therapy and lipid profile: an update | European Journal of Cancer, Supplement | 2004 | 22 |
| 46 | 4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma | European Journal of Cancer, Supplement | 2007 | 22 |
| 47 | 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma | European Journal of Cancer, Supplement | 2003 | 21 |
| 48 | 6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 | European Journal of Cancer, Supplement | 2009 | 21 |
| 49 | The need for aminoglycosides in combination with β-lactams for high-risk, febrile neutropaenic patients with leukaemia | European Journal of Cancer, Supplement | 2007 | 20 |
| 50 | 1156 POSTER High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo | European Journal of Cancer, Supplement | 2007 | 19 |
